SanReno Therapeutics, a two-year old biopharma company with headquarters in Shanghai, China, has been acquired by Novartis, giving the Switzerland-based multinational two late-stage assets for immunoglobulin A nephropathy (IgAN), a rare kidney disease. The value of the transaction, which was announced on 5 January, wasn’t disclosed. SanReno was founded in late 2021 as a joint venture between a group of venture capitalists and Chinook Therapeutics Inc, a US company with two Phase 3 assets for IgAN.
